5 completed, 2 active not recruiting, 1 terminated, 1 unknown. 3 Not applicable, 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Spinal Muscular Atrophy Type II: new trials by email Literature Review of Spinal Muscular Atrophy Type II trials Research Report on Spinal Muscular Atrophy Type II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Not applicable | Completed | Marco Capogrosso | 3 | 2024-05-31 | 2026-10-23 |
| Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | Completed | Novartis | 69 | 2023-07-05 | 2024-10-09 | |
| Spinal Cord Gray Matter Imaging in Spinal Muscular Atrophy MRI - Spinal Muscular Atrophy Type III, Spinal Muscular Atrophy Type II | Unknown | University Hospital, Basel, Switzerland | 52 | 2020-08-17 | 2023-11-18 | |
| Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi - Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | Phase 3 | Active not recruiting | Novartis Gene Therapies | 85 | 2020-02-10 | 2026-09-24 |
| Body Weight Support Harness System in Spinal Muscular Atrophy In-home body weight support harness system - Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | Not applicable | Completed | Nationwide Children's Hospital | 33 | 2018-09-07 | 2024-07-22 |
| Spinraza in Adult Spinal Muscular Atrophy Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II | Active not recruiting | Washington University School of Medicine | 148 | 2018-08-16 | 2024-11-20 | |
| Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy Use of the ATLAS 2025 exoskeleton at home - Spinal Muscular Atrophy Type II | Not applicable | Completed | MarsiBionics | 3 | 2017-12-01 | 2022-06-13 |
| Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients. Olesoxime, Placebo - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant | Phase 2 | Completed | Hoffmann-La Roche | 165 | 2010-11-01 | 2016-11-22 |
| Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III sodium phenylbutyrate - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III | Phase 1 / Phase 2 | Terminated | Westat | 9 | 2008-01-01 | 2010-09-08 |
Spinal Muscular Atrophies of Childhood (9) · Muscular Atrophy, Spinal (4) · Motor Activity (1) · Motor Neuron Disease (1) · Spinal muscular atrophy 4 (1)
Central Nervous System Diseases (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Heredodegenerative Disorders, Nervous System (9) · Nervous System Diseases (9) · Neurodegenerative Diseases (9) · Neuromuscular Diseases (9) · Spinal Cord Diseases (9) · Motor Neuron Disease (8) · Muscular Atrophy, Spinal (5) · Behavior (1)
4-phenylbutyric acid (1) · Zolgensma (1) · bbc3 protein, zebrafish (1) · olesoxime (1)
Hoffmann-La Roche (1) · Marco Capogrosso (1) · MarsiBionics (1) · Nationwide Children's Hospital (1) · Novartis (1) · Novartis Gene Therapies (1) · University Hospital, Basel, Switzerland (1) · Washington University School of Medicine (1) · Westat (1)
United States (6) · Belgium (2) · Canada (2) · France (2) · Italy (2) · United Kingdom (2) · Australia (1) · Germany (1) · Japan (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Craig Zaidman, MD (1) · Enrico Bertini, MD (1) · Marco Capogrosso (1) · Megan A Iammarino, DPT (1) · Peter R. Gilbert, ScM (1) · Sitra Tauscher-Wisniewski, MD (1)
PMID 28460889, PMID 34383289, PMID 38502672, PMID 39287519
2019 (1), N01NS42361 (1)